The generalized myasthenia gravis treatment pipeline features several promising late-stage candidates, including IMVT-1402 (Immunovant/Roivant Sciences), Descartes-08 (Cartesian Therapeutics), Remibrutinib (Novartis),…
The partnership reflects growing demand for specialized payments infrastructure among high-scale mobility platforms. Nicosia, Cyprus, April 15, 2026 (GLOBE NEWSWIRE)…
Allschwil, Switzerland, April 15, 2026 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs…